- Home
- CRIS vs BCG Comparison
CRIS vs BCG Comparison
Compare CRIS & BCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRIS | BCG |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 24.4M |
| IPO Year | 2000 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CRIS | BCG |
|---|---|---|
| Price | $1.53 | $1.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 262.0K | 51.7K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 91.57 | ★ 112.50 |
| EPS | N/A | ★ 0.08 |
| Revenue | $9,898,000.00 | ★ $187,144,000.00 |
| Revenue This Year | $27.10 | N/A |
| Revenue Next Year | $67.74 | N/A |
| P/E Ratio | ★ N/A | $17.50 |
| Revenue Growth | ★ 31.50 | 10.80 |
| 52 Week Low | $0.18 | $1.26 |
| 52 Week High | $6.74 | $3.44 |
Technical Indicators
Market Signals| Indicator | CRIS | BCG |
|---|---|---|
| Relative Strength Index (RSI) | 28.11 | 44.71 |
| Support Level | $1.54 | $1.26 |
| Resistance Level | $5.55 | $1.62 |
| Average True Range (ATR) | 0.48 | 0.10 |
| MACD | -0.30 | 0.00 |
| Stochastic Oscillator | 0.67 | 35.00 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About BCG Binah Capital Group Inc.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.